Praxis Precision Medicines, Inc. (PRAX) |
|
0.8171 -0.037 (-4.3%)
|
03-24 16:00 |
|
Open: |
0.8365 |
Pre. Close: |
0.8538 |
|
High:
|
0.88 |
Low:
|
0.8101 |
|
Volume:
|
964,995 |
Market Cap:
|
48(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:56 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.05  One year: 4.35 |
| Support: |
Support1: 0.81 Support2: 0.67 |
| Resistance: |
Resistance1: 2.61 Resistance2: 3.73 |
| Pivot: |
1.03 |
| Moving Average: |
MA(5): 0.94 MA(20): 1.44
MA(100): 2.62 MA(250): 3.91 |
| MACD: |
MACD(12,26): -0.7  Signal(9): -0.7 |
| Stochastic oscillator: |
%K(14,3): 2.1 %D(3): 2.2 |
| RSI: |
RSI(14): 17.5 |
| 52-week: |
High: 13.32 Low: 0.81 |
| Average Vol(K): |
3-Month: 2,096 (K) 10-Days: 1,665 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PRAX ] has closed below the lower bollinger band by 9.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 75% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.88 - 0.89 |
0.89 - 0.89 |
|
Low:
|
0.8 - 0.8 |
0.8 - 0.81 |
|
Close:
|
0.81 - 0.82 |
0.82 - 0.83 |
|
Company Description |
|
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. |
Headline News |
Wed, 15 Mar 2023
Silicon Valley Bank collapse: For some biotechs, not all traditional ... - The Business Journals
Tue, 14 Mar 2023
Praxis Precision Medicines Inc (PRAX) Down 6.36% in Premarket Trading - InvestorsObserver
Thu, 09 Mar 2023
Praxis Precision Medicines Inc (PRAX) Down 2.88% in Premarket Trading - InvestorsObserver
Fri, 03 Mar 2023
Healthcare Stocks Making Moves Friday: KALA, SEER, ARDX, LXRX, PRAX, VERU, SMMT, PBYI - InvestorsObserver
Fri, 03 Mar 2023
Praxis Precision Medicines Shares Hit 52-Week Low After Ulixacaltamide Primary Endpoint Misses Statistical Significance - MarketWatch
Fri, 03 Mar 2023
Praxis Precision Medicines Announces Topline Results from the ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
47 (M) |
| Shares Float |
36 (M) |
|
% Held by Insiders
|
0.6 (%) |
|
% Held by Institutions
|
89.6 (%) |
|
Shares Short
|
2,140 (K) |
|
Shares Short P.Month
|
1,910 (K) |
Stock Financials |
|
EPS
|
-3.48 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.65 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-65.9 |
|
Return on Equity (ttm)
|
-131 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-4.56 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-185 (M) |
|
Levered Free Cash Flow
|
-166 (M) |
Stock Valuations |
|
PE Ratio
|
-0.24 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
0.12 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.21 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
